OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Total Liabilities
OSE Immunotherapeutics SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Liabilities
€59.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€318.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Liabilities
€102.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
20%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€97.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€118.5m
|
CAGR 3-Years
53%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities
€135.1m
|
CAGR 3-Years
43%
|
CAGR 5-Years
28%
|
CAGR 10-Years
19%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Total Liabilities?
Total Liabilities
59.5m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Total Liabilities amounts to 59.5m EUR.
What is OSE Immunotherapeutics SA's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
13%
Over the last year, the Total Liabilities growth was 3%. The average annual Total Liabilities growth rates for OSE Immunotherapeutics SA have been 9% over the past three years , 13% over the past five years .
You don't have any saved screeners yet